Hycells HiMag™ Immune Cell Sorting Technology Platform | High Purity, High Viability, Versatile Applications—Redefining the Benchmark for Cell Sorting
Release Date:
2026-06-22 16:15
With the rapid advancement of cell and gene therapies, the industry is placing increasingly stringent demands on the performance, batch-to-batch consistency, and supply-chain reliability of cell-sorting reagents. At present, the domestic market for sorting magnetic beads remains dominated by imported brands, and their high cost of use and uncertain supply have become significant barriers to both research and industrialization in China.
Wuxi Hycells Biotechnology Co., Ltd., leveraging its independently developed superparamagnetic nanomagnetic beads and high‑gradient magnetic separation core technologies, has launched the HiMag™ series of human cell‑sorting products, encompassing key product categories such as CD4‑positive, CD8‑positive, and CD14‑positive sorting beads, CD3‑negative sorting reagents, NK‑cell‑negative sorting beads, and a TCR‑αβ T‑cell depletion kit. The company has achieved end‑to‑end independent control—spanning core raw materials, reagent formulations, sorting instruments, and standardized workflows—dedicated to providing domestic research institutions and biopharmaceutical companies with an integrated immune cell‑sorting solution that delivers high performance, exceptional cost‑effectiveness, and broad applicability across diverse experimental settings.
HiMag™ Technology Platform: Architecture and Underlying Advantages
The HiMag™ cell sorting platform is built around self-developed superparamagnetic nanomagnetic beads, complemented by high‑gradient magnetic separation columns, dedicated sorters, and specialized sorting buffers, thereby establishing a comprehensive pillar‑based sorting system. The platform’s technological architecture is fully aligned with leading international products and has undergone systematic optimization to address domestic sample characteristics, experimental workflows, and industrialization requirements:
High-performance nanomagnetic beads: superparamagnetic, with uniform particle size and low non-specific adsorption, ensuring a gentle sorting process with high specificity.
Outstanding sorting performance: sorting purity ≥90% (with most samples ≥95%), recovery rate 60%–96%, and cell viability ≥90%.
Simple operating procedure: The pillar‑type separation process can be completed in under one hour, with no need for specialized equipment.
Broad sample compatibility: Suitable for a variety of sample types, including whole blood, apheresis products, and fresh or cryopreserved PBMCs, with high batch-to-batch consistency.
Significant advantages in domestic substitution: performance meets the level of comparable international products, with clear cost advantages and stable, controllable delivery timelines, ensuring supply chain security.
Sorting principle: The packing material inside the sorting column is… Magnetic microspheres The external magnetic field can be amplified up to 10,000 times its original strength, generating a high‑gradient magnetic field. Target cells labeled with superparamagnetic nanobeads are specifically retained as they pass through the sorting column, while unlabeled cells elute directly with the buffer. After removing the magnetic field and gently washing the column, highly pure, highly viable target cells can be obtained.
A comprehensive product portfolio that covers a wide range of sorting strategies.
The HiMag™ product line encompasses three major technological platforms—positive selection, negative selection, and cell depletion—and includes mainstream immune cell‑sorting kits for CD3, CD4, CD8, CD14, NK cells, TCR‑αβ T cells, and more. It is complemented by a comprehensive suite of consumables, such as sorting columns, sorters, sorting racks, universal magnetic beads, and dedicated buffers, forming an end‑to‑end product portfolio that spans reagents to instruments. Products are available in two standard formats—10‑test and 100‑test—offering flexible scalability to accommodate varying experimental throughput levels.
Yangxuan Series (CD4, CD8, CD14): Suitable for T-cell subset sorting in CAR‑T/TCR‑T cell manufacturing, monocyte/macrophage research, and cytotoxic T-cell functional analysis, among other applications. Sorted cells can be directly used for downstream culture or RNA extraction.
Negative selection series (total T cells, NK cells): Employing a non‑target cell depletion strategy, this approach enables gentle, contactless, and non‑stimulatory sorting, making it particularly well suited for downstream expansion cultures and functional assays.
TCR-αβ T Cell Depletion Kit: Efficiently depletes αβ T cells, enabling NK and… γδT Provides technical support for amplification.
Supporting consumables system: sorting columns (small/medium), universal sorting rack, sorting buffer, streptavidin/ Biotin antagonist Universal magnetic beads offer flexible support for both direct and indirect labeling‑based sorting protocols, expanding the scope of applications.
Performance Comparison
Hycells conducted systematic parallel comparative studies with leading international brands, using commonly employed domestic sample types such as whole blood, apheresis‑derived products, and cryopreserved PBMCs. The key performance indicators are as follows:
1. Cell viability: There is no significant difference before and after sorting; the post-sorting viability of HiMag™ remains stable at ≥90%, on par with imported products, thereby ensuring the integrity of cellular functions.
2. Cell Purity : The purity of mainstream products such as CD4, CD8, CD14, NK cells, and CD3 cells is ≥90%, with most samples achieving over 95%, reaching the same level as imported counterparts.
3. Cell recovery rate: The overall recovery rate ranges from 60% to 96%, and it outperforms certain imported products, particularly in complex cryopreserved samples and low‑activity primary cells.
4. Cell Function Validation:
Induction after CD14⁺ sorting M0 macrophages Flow cytometry demonstrated equivalent expression levels of the CD14⁺, CD11c⁺, CD80⁺, and CD68⁺ markers compared with the reference product.
Following negative selection, CD3⁺ T cells exhibited no significant differences in expansion capacity or expression of activation markers compared with imported products after 7 days of activation and culture.
In functional assays involving in vitro induction, expansion, and activation of sorted cells, their differentiation and proliferation capacities fully meet the stringent requirements of both basic research and the commercialization of cell therapies.
Core Application Scenarios
The HiMag™ technology platform, with its high stability and versatile adaptability across multiple scenarios, provides comprehensive support to the biopharmaceutical industry chain:
Basic immunology research: subpopulation classification of immune cells, cellular phenotyping, mechanisms of cell–cell interactions, antigen presentation mechanisms, and studies on lymphocyte functions, among others.
Tumor Immunology Research: Sorting of Tumor-Infiltrating Lymphocytes (TILs), Analysis of the Tumor Immune Microenvironment, and Investigation of the Antitumor Mechanisms of Cytotoxic T Cells and Natural Killer (NK) Cells.
Cell‑therapy industrialization: In the manufacturing of cell‑therapy products such as CAR‑T, TCR‑T, and CAR‑NK, immune‑cell sorting, subtype enrichment, and purification ensure a stable supply of high‑quality starting materials for large‑scale production.
Cutting-edge omics research: High-purity cell enrichment prior to experiments such as single-cell sequencing, transcriptome sequencing, and proteomic analysis, ensuring data reliability from the outset.
By developing and manufacturing its products in‑house across the entire value chain, Hycells not only ensures that product performance meets international standards but also effectively reduces operating costs and significantly shortens delivery lead times. Its HiMag™ sorting technology platform delivers purer separations, healthier cells, and broader application possibilities, providing a reliable, domestically sourced solution to support the advancement of life sciences research and the cell‑therapy industry in China.
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board